Discussion of key current medication safety challenges within healthcare with a focus on the safe use of valproate; inspiring partnership across the system.

Why it’s important

Due to the known significant risk of serious harm to a baby after exposure to valproate in pregnancy new regulatory measures aim to ensure safer use of valproate.  Implementation of these new regulatory measures require a collaborative and system wide approach to ensure safe and sustainable safety improvements.

What will be covered

  • A discussion of the new regulations related to valproate use and the implications for the system.
  • Identification of challenges with implementation of new regulations within existing clinical pathways, and discussion of potential innovate solutions.
  •  ‘Lived experience’ will be shared to understand the impact of these new regulations for individuals.
  •  Shared exemplar practices where valproate safety has been reviewed in light of the new regulations, to enable reflection of local practice and consideration for implementation at a local and system level.

Speakers

A range of speakers from SPS and other organisations will run this event.

Non-SPS Speakers

Dr Henrietta Hughes OBE

Patient Safety Commissioner

Tony Jamieson

Medicines Safety Improvement Programme Lead NHS England

More speakers to be announced.

SPS Speakers

Learn more about SPS team member who are speaking.